The 3TR Molecular Pathobiology-Driven Precision Therapy in RA study (3TR Precis-The-RA)
[IRAS Project No. 289895]
Status: In set-up
This study is part of the Taxonomy, Treatments, Targets and Remission (3TR) project which is a large scale public-private initiative that will provide new insights into why medicines are effective or ineffective across 7 different immune-mediated diseases (Chronic obstructive pulmonary disease, Asthma, Crohn’s Disease, Ulcerative Colitis, Multiple Sclerosis, Systemic Lupus Erythematosus, Rheumatoid Arthritis). The project will study over 50,000 patient samples across 50 clinical trials with the aim to improve disease management. There are 69 academic and industry partners participating, covering 15 European countries.
The 3TR Precis-The-RA study aims to test whether RNA signatures (biomarkers), in the tissue which surrounds the joints (synovial tissue) from patients with Rheumatoid Arthritis are predictive of response to drug treatments such as biologic disease-modifying anti-rheumatic drugs (b-DMARDs) and targeted synthetic disease-modifying anti-rheumatic drugs (ts-DMARDs). Rheumatoid arthritis patients will undergo a biopsy of their joint, and then will receive either sarilumab, tocilizumab, or tofacitinib. Half of the patients will receive the drug randomly, and the other half will be treated according to their biomarkers. Patients will attend 4-weekly visits up to 12 weeks, followed by a 30-day safety follow-up visit.
3TR Precis-The-RA & Data-Resource Metrics
We aim to recruit approximately 200 patients. Synovial tissue, blood, and optional urine, saliva, and stool samples will be collected.